These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 31046547)

  • 21. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
    Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
    Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody.
    Rattanapisit K; Phakham T; Buranapraditkun S; Siriwattananon K; Boonkrai C; Pisitkun T; Hirankarn N; Strasser R; Abe Y; Phoolcharoen W
    Sci Rep; 2019 Oct; 9(1):15205. PubMed ID: 31645587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
    Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
    Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
    Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
    Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
    Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
    Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
    Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM
    MAbs; 2021; 13(1):1980942. PubMed ID: 34850665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.
    Kim HM; Kim KJ; Lee K; Yoon MJ; Choih J; Hong TJ; Cho EJ; Jung HJ; Kim J; Park JS; Na HY; Heo YS; Park CG; Park H; Han S; Bae D
    BMC Immunol; 2024 May; 25(1):29. PubMed ID: 38730320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
    Plitnick LM; Hutchins B; Dubey S; Li N; Amin RP; Born S; Mangadu R; Phillips JH; Sriram V; Herzyk DJ
    J Immunotoxicol; 2020 Dec; 17(1):175-185. PubMed ID: 33078980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets.
    Ching KH; Collarini EJ; Abdiche YN; Bedinger D; Pedersen D; Izquierdo S; Harriman R; Zhu L; Etches RJ; van de Lavoir MC; Harriman WD; Leighton PA
    MAbs; 2018 Jan; 10(1):71-80. PubMed ID: 29035625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody repertoire analysis of mouse immunization protocols using microfluidics and molecular genomics.
    Asensio MA; Lim YW; Wayham N; Stadtmiller K; Edgar RC; Leong J; Leong R; Mizrahi RA; Adams MS; Simons JF; Spindler MJ; Johnson DS; Adler AS
    MAbs; 2019 Jul; 11(5):870-883. PubMed ID: 30898066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
    Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
    Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
    Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
    Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics.
    Adler AS; Mizrahi RA; Spindler MJ; Adams MS; Asensio MA; Edgar RC; Leong J; Leong R; Johnson DS
    MAbs; 2017; 9(8):1270-1281. PubMed ID: 28846506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
    Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
    Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
    Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
    Front Immunol; 2020; 11():895. PubMed ID: 32528470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development of IgHV family specific nucleic acid vaccine against lymphoma by construction of fusion gene of immunoglobulin heavy chain variable region and cytokine].
    Liu H; Zhu P; Lin NJ; Zhang Y; Bu DF; Wang YJ; Wang YQ; Yang Y
    Zhonghua Yi Xue Za Zhi; 2004 Jan; 84(1):48-53. PubMed ID: 14990159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.